This February, Xavier Horton became the first person in Alabama and the 27th person in the nation to receive deep brain stimulation (DBS) for epilepsy.
The neurology team at UAB first mentioned DBS to Horton, who has had seizures since he was 12 years old, in 2016 while it was still in the experimental stage. The procedure has been approved for Parkinson's disease since 1997, and has since become a treatment option for dystonia, essential tremor and drug-resistant obsessive-compulsive disorder. DBS was approved for epilepsy in 2018.
Neurosurgeons insert narrow electrodes into the brain, specifically into the anterior thalamic nucleus in both hemispheres. The electrodes are connected to a neurostimulator implanted in the patient's chest, not unlike a pacemaker, by wires just beneath the skin.
"The neurostimulator supplies an electric current that disrupts the electrical activity responsible for triggering the seizures, basically interrupting a seizure before it can get started," said Jerzy Szaflarski, MD, PhD, director of the UAB Epilepsy Center and a professor in the Department of Neurology, School of Medicine. "The path of the electrical impulses that trigger seizures frequently passes through the anterior thalamic nucleus, so it's the most appropriate target to intercept and modify those impulses via the current from the stimulator."
Nicole Bentley, MD
"We employ new techniques of magnetic resonance imaging for planning and targeting the nucleus in our surgical approach," said Nicole Bentley, MD, an assistant professor in the Department of Neurosurgery. "We then merge the MRI images with a CT scan done in the operating room to place the electrodes in the best location for maximum effect."
A DBS lead is implanted into each of the brain's two hemispheres. There are four contacts on each of the leads, and each contact can be modified in power and intensity. This allows for thousands of possible combinations to paint the most effective pattern of electrical activity for each patient to alleviate their seizures. The system is turned on and fine-tuned following the surgery.
Horton has what is known as frontal lobe epilepsy, which leads to frontal onset seizures.
"These are small seizures, and I might have several a month," Horton said. "They might last a few seconds, or last for more than a minute."
It has made it hard to hold a job or drive a car, since Horton had no way of anticipating when a seizure might strike.
"We anticipate a reduction of seizures of 60 to 70 percent," Szaflarski said. "If he has five a month, the DBS system might reduce that to just one per month. There is evidence that the repeated application of the current over time could also reduce the number of seizures even more."
DBS is not for every patient with epilepsy, but it is an important new option.
"It's not a cure in most cases, but it is an option for treatment," Bentley said. "Medication is the first treatment. If that fails and seizures cannot be localized to one specific area, DBS surgery may be an option. For some patients, there are no other viable options."
DBS is not the only technology that uses neurostimulation to treat epilepsy. VNS stimulates the vagus nerve in the neck and does not involve brain surgery. RNS uses leads implanted at the site of seizure onset, with the battery implanted in the top of the skull to produce electrical pulses when seizure activity is noted.
"DBS is the newest technique, but all of these are options, depending on the needs of the patient," Szaflarski said.
It will take a few months for Horton to know just how well DBS is working for him. Along with his physicians, he will monitor the frequency and severity of his seizures over time. His initial reaction has been positive, and he feels as if the frequency of his seizures has lessened.
"I've had a lot of restrictions in the past," Horton said. "I'm hoping that DBS will allow me to start doing those things -- get a job and a career, move out from my parents. This is a good start."